Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer.

Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer.
复制标题

DOI:
10.3389/fonc.2022.812159
复制
发表时间:
2022
影响因子:
4.7
通讯作者:
Clayburgh D
Clayburgh D
中科院分区:
医学3区
文献类型:
--
作者:
Olson B;Edwards J;Degnin C;Santucci N;Buncke M;Hu J;Chen Y;Fuller CD;Geltzeiler M;Grossberg AJ;Clayburgh D

文献摘要

参考文献

被引文献

相似文献

Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC. This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival. Skeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm2/m2 (men) and 11.1 cm2/m2 (women) were best predictive of L3 sarcopenia thresholds. Applying these C3 thresholds to a cohort of patients with neck imaging alone revealed that C3 sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85). This study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC.
DOI: 10.1007/s13539-010-0016-0
发表时间: 2010-12
期刊: Journal of cachexia, sarcopenia and muscle
影响因子: --
作者:
Kilgour RD;Vigano A;Trutschnigg B;Hornby L;Lucar E;Bacon SL;Morais JA
通讯作者: Morais JA
DOI: 10.1001/jamaoncol.2018.0137
发表时间: 2018-06-01
期刊: JAMA ONCOLOGY
影响因子: 28.4
作者:
Caan, Bette J.;Feliciano, Elizabeth M. Cespedes;Chen, Wendy Y.
通讯作者: Chen, Wendy Y.
DOI: 10.1007/s00405-019-05307-w
发表时间: 2019-04-01
影响因子: 2.6
作者:
Bril, S. I.;Wendrich, A. W.;de Bree, R.
通讯作者: de Bree, R.
DOI: 10.1016/j.oraloncology.2021.105617
发表时间: 2021-11-05
期刊: ORAL ONCOLOGY
影响因子: 4.8
作者:
Bril, S., I;Chargi, N.;de Bree, R.
通讯作者: de Bree, R.
DOI: 10.1038/nrdp.2017.105
发表时间: 2018-01-18
影响因子: 81.5
作者:
Baracos, Vickie E.;Martin, Lisa;Fearon, Kenneth C. H.
通讯作者: Fearon, Kenneth C. H.